Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage

Eric Dein; Rebecca Manno; Abrahim Syed; Homeyra Douglas; Duvuru Geetha; Homa Timlin

doi:10.7759/cureus.2832

Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage

Cureus. 2018 Jun 18;10(6):e2832. doi: 10.7759/cureus.2832.

Authors

Eric Dein¹, Rebecca Manno², Abrahim Syed², Homeyra Douglas³, Duvuru Geetha⁴, Homa Timlin⁵

Affiliations

¹ Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, USA.
² Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, USA.
³ Cardiology, University Hospital Aintree, Liverpool, GBR.
⁴ Medicine, The Johns Hopkins University School of Medicine, Baltimore, USA.
⁵ Medicine, The Johns Hopkins University School of Medicine, Essex, USA.

Abstract

Ranolazine received Food and Drug Administration (FDA) approval in 2006 for the treatment of chronic angina. Ranolazine has previously been linked to the development of statin-induced myopathy, because it also inhibits CYP3A4, which increases serum statin levels. In the absence of concomitant statin therapy, elevated creatinine kinase (CK) and myalgias on ranolazine monotherapy has never been reported.

Keywords: elevated ck; ranolazine.

Publication types

Case Reports